News & Perspective

Jan 17, 2007

Jan 17, 2007

HHS funds work on dose-sparing H5N1 vaccines

(CIDRAP News) – In an effort to stretch the nation's supply of vaccines for a potential influenza pandemic, federal health officials today announced contracts totaling $132.5 million to help three companies develop dose-sparing substances, or adjuvants, to be used with H5N1 flu vaccines.